221 related articles for article (PubMed ID: 25951238)
1. JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
Kuo YT; Liu YL; Adebayo BO; Shih PH; Lee WH; Wang LS; Liao YF; Hsu WM; Yeh CT; Lin CM
PLoS One; 2015; 10(5):e0125343. PubMed ID: 25951238
[TBL] [Abstract][Full Text] [Related]
2. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Kuo KT; Huang WC; Bamodu OA; Lee WH; Wang CH; Hsiao M; Wang LS; Yeh CT
Clin Epigenetics; 2018 Aug; 10(1):107. PubMed ID: 30092824
[TBL] [Abstract][Full Text] [Related]
3. Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma.
Lin CS; Lin YC; Adebayo BO; Wu A; Chen JH; Peng YJ; Cheng MF; Lee WH; Hsiao M; Chao TY; Yeh CT
Cancer Lett; 2015 Nov; 368(1):36-45. PubMed ID: 26184998
[TBL] [Abstract][Full Text] [Related]
4. Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Zhang L; Sokolowski N; Atmadibrata B; Liu T
Oncol Rep; 2014 Apr; 31(4):1935-9. PubMed ID: 24481781
[TBL] [Abstract][Full Text] [Related]
5. JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
Shen X; Zhuang Z; Zhang Y; Chen Z; Shen L; Pu W; Chen L; Xu Z
Tumour Biol; 2015 Sep; 36(9):7133-42. PubMed ID: 25877751
[TBL] [Abstract][Full Text] [Related]
6. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW
Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630
[TBL] [Abstract][Full Text] [Related]
7. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Li Q; Shi L; Gui B; Yu W; Wang J; Zhang D; Han X; Yao Z; Shang Y
Cancer Res; 2011 Nov; 71(21):6899-908. PubMed ID: 21937684
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast.
Zhao LH; Liu HG
Genet Mol Res; 2015 May; 14(2):5417-26. PubMed ID: 26125737
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma.
Sun LL; Sun XX; Xu XE; Zhu MX; Wu ZY; Shen JH; Wu JY; Huang Q; Li EM; Xu LY
Acta Histochem; 2013 Jan; 115(1):56-62. PubMed ID: 22534467
[TBL] [Abstract][Full Text] [Related]
11. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.
Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM
Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
[TBL] [Abstract][Full Text] [Related]
13. Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma.
Fang L; Zhao J; Wang D; Zhu L; Wang J; Jiang K
Int J Mol Med; 2016 Jul; 38(1):172-82. PubMed ID: 27246838
[TBL] [Abstract][Full Text] [Related]
14. JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.
Facompre ND; Harmeyer KM; Sole X; Kabraji S; Belden Z; Sahu V; Whelan K; Tanaka K; Weinstein GS; Montone KT; Roesch A; Gimotty PA; Herlyn M; Rustgi AK; Nakagawa H; Ramaswamy S; Basu D
Cancer Res; 2016 Sep; 76(18):5538-49. PubMed ID: 27488530
[TBL] [Abstract][Full Text] [Related]
15. JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Su H; Ma X; Huang Y; Han H; Zou Y; Huang W
Int J Clin Exp Pathol; 2015; 8(1):171-83. PubMed ID: 25755704
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Kuźbicki Ł; Lange D; Stanek-Widera A; Chwirot BW
BMC Cancer; 2017 Dec; 17(1):854. PubMed ID: 29246117
[TBL] [Abstract][Full Text] [Related]
17. Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy.
Jandl T; Revskaya E; Jiang Z; Harris M; Dorokhova O; Tsukrov D; Casadevall A; Dadachova E
Nucl Med Biol; 2013 Feb; 40(2):177-81. PubMed ID: 23146306
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.
Zhang J; An X; Han Y; Ma R; Yang K; Zhang L; Chi J; Li W; Llobet-Navas D; Xu Y; Jiang Y
Cell Death Dis; 2016 Sep; 7(9):e2358. PubMed ID: 27584795
[TBL] [Abstract][Full Text] [Related]
19. JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer.
Mocavini I; Pippa S; Licursi V; Paci P; Trisciuoglio D; Mannironi C; Presutti C; Negri R
Cancer Sci; 2019 Apr; 110(4):1232-1243. PubMed ID: 30588710
[TBL] [Abstract][Full Text] [Related]
20. PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Cui Z; Song L; Hou Z; Han Y; Hu Y; Wu Y; Chen W; Mao L
Oncol Rep; 2015 May; 33(5):2454-60. PubMed ID: 25777981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
